On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal

Mechanism of Action of Trazodone: a Multifunctional Drug

(2016) Stephen M. Stahl   CNS SPECTRUMS

?7-Nicotinic Receptors and Cognition

(2013) Edward D. Levin   CURRENT DRUG TARGETS

Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics

(2012) Florent G. Revel et al.   BIOLOGICAL PSYCHIATRY

Ketamine for Depression: Where Do We Go from Here?

(2012) Marije aan het Rot et al.   BIOLOGICAL PSYCHIATRY

Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex

(2012) Huali Lin et al.   BRAIN RESEARCH

Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: anin vivomicrodialysis study in mice

(2012) Hai T Nguyen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ketamine for Treatment-Resistant Unipolar Depression

(2012) Sanjay J. Mathew et al.   CNS DRUGS

NPY Intraperitoneal Injections Produce Antidepressant-Like Effects and Downregulate BDNF in the Rat Hypothalamus

(2012) Francesca Gelfo et al.   CNS Neuroscience & Therapeutics

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

(2012) Carol R. Reed et al.   CURRENT MEDICAL RESEARCH AND OPINION

Emerging Targets for the Pharmacological Treatment of Depression: Focus on Melatonergic System

(2012) Mario Catena-Dell'Osso et al.   CURRENT MEDICINAL CHEMISTRY

Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia

(2012) H. Y. Meltzer et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review

(2012) Jonathan C. Lee et al.   CURRENT PHARMACEUTICAL DESIGN

Can we discover pharmacological promiscuity early in the drug discovery process?

(2012) Jens-Uwe Peters et al.   DRUG DISCOVERY TODAY

5-HT6receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia

(2012) Julie Meffre et al.   EMBO Molecular Medicine

Emerging drugs for major depressive disorder

(2012) Kevin Ryan Connolly et al.   EXPERT OPINION ON EMERGING DRUGS

5-HT2 ligands in the treatment of anxiety and depression

(2012) Gaël Quesseveur et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study

(2012) Seyed-Hesameddin Abbasi et al.   JOURNAL OF AFFECTIVE DISORDERS

Steric Hindrance Mutagenesis in the Conserved Extracellular Vestibule Impedes Allosteric Binding of Antidepressants to the Serotonin Transporter

(2012) Per Plenge et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Agomelatine Prevents Relapse in Generalized Anxiety Disorder

(2012) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHIATRY

Combination of Antidepressants in the Treatment of Major Depressive Disorder

(2012) Fábio Lopes Rocha et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

(2012) Lobna Ibrahim et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice

(2012) Martin Egeland et al.   JOURNAL OF NEUROCHEMISTRY

Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, and Zen Meditation for Depression, Anxiety, Pain, and Psychological Distress

(2012) WILLIAM R. MARCHAND   Journal of Psychiatric Practice

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

(2012) Kari R Nations et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The hidden third: improving outcome in treatment-resistant depression

(2012) Thomas E Schlaepfer et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Neurokinin-1 Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review

(2012) L. V. dos Santos et al.   JNCI-Journal of the National Cancer Institute

The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: Significance for the use as anxiolytic/antidepressant drug

(2012) Dragos Inta et al.   NEUROPHARMACOLOGY

An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy

(2012) Mark J. Millan   NEUROPHARMACOLOGY

Serum Ghrelin Levels and the Effects of Antidepressants in Major Depressive Disorder and Panic Disorder

(2012) Yoshinobu Ishitobi et al.   NEUROPSYCHOBIOLOGY

Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice

(2012) Valeria Paola Carlini et al.   PEPTIDES

Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat

(2012) Daniella Johansson et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents

(2012) Ronald S. Duman et al.   TRENDS IN NEUROSCIENCES

Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients

(2012) Daniela L. Krause et al.   INFLAMMOPHARMACOLOGY

Efficacy of light therapy for perinatal depression: a review

(2012) Shannon K Crowley et al.   Journal of Physiological Anthropology

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study

(2011) A. John Rush et al.   AMERICAN JOURNAL OF PSYCHIATRY

Discovery of Lu AA33810: A highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder

(2011) Mathivanan Packiarajan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors

(2011) Amanda J Sales et al.   BRITISH JOURNAL OF PHARMACOLOGY

Vilazodone

(2011) James E. Frampton   CNS DRUGS

MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues

(2011) Mark J Millan   CURRENT OPINION IN PHARMACOLOGY

ECNP Summit on the future of CNS drug research in Europe 2011: Report prepared for ECNP by David Nutt and Guy Goodwin

(2011) David Nutt et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Transcranial direct current stimulation for the outpatient treatment of poor-responder depressed patients

(2011) B. Dell’Osso et al.   EUROPEAN PSYCHIATRY

Current research trends in early life stress and depression: Review of human studies on sensitive periods, gene–environment interactions, and epigenetics

(2011) Christine Heim et al.   EXPERIMENTAL NEUROLOGY

Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α2-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine

(2011) Florence Serres et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Rapid-acting antidepressant strategies: mechanisms of action

(2011) Blynn G. Bunney et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

mTOR activation is required for the antidepressant effects of mGluR2/3 blockade

(2011) Jason M. Dwyer et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report

(2011) William V. Bobo et al.   JOURNAL OF AFFECTIVE DISORDERS

Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder

(2011) Emiliangelo Ratti et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression

(2011) Brice Campo et al.   JOURNAL OF NEUROGENETICS

Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA)

(2011) B. Di Cara et al.   JOURNAL OF NEUROSCIENCE

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial

(2011) Pierre Tran et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Depression drug disappoints

(2011) Heidi Ledford   NATURE

MicroRNAs and depression

(2011) Sophie Mouillet-Richard et al.   NEUROBIOLOGY OF DISEASE

Selective p38α MAPK Deletion in Serotonergic Neurons Produces Stress Resilience in Models of Depression and Addiction

(2011) Michael R. Bruchas et al.   NEURON

Epigenetic Treatments for Cognitive Impairments

(2011) Jeremy J Day et al.   NEUROPSYCHOPHARMACOLOGY

Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex

(2011) David JG Watson et al.   NEUROPSYCHOPHARMACOLOGY

Functional Biomarkers of Depression: Diagnosis, Treatment and Pathophysiology

(2011) Heath D Schmidt et al.   NEUROPSYCHOPHARMACOLOGY

Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy

(2011) Ouissame Mnie-Filali et al.   NEUROPSYCHOPHARMACOLOGY

Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression

(2011) Brian Leonard et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Fluoxetine, 17-β estradiol or folic acid combined with intra-lateral septal infusions of neuropeptide Y produced antidepressant-like actions in ovariectomized rats forced to swim

(2011) Miguel Molina-Hernández et al.   PEPTIDES

Immune system to brain signaling: Neuropsychopharmacological implications

(2011) Lucile Capuron et al.   PHARMACOLOGY & THERAPEUTICS

Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: A comparison of SSR180711 and PNU-282987

(2011) Jesper T. Andreasen et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling

(2011) Stefania Risso Bradley et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans

(2011) J. L. Warner-Schmidt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder

(2011) Courtney S. Jernigan et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Intra-lateral septal infusions of folic acid alone or combined with various antidepressant drugs produce antidepressant-like actions in male Wistar rats forced to swim

(2011) Miguel Molina-Hernández et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action

(2011) Huailing Zhong et al.   PSYCHOPHARMACOLOGY

Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings

(2011) Susanne Graef et al.   PSYCHOPHARMACOLOGY

Systems genetics for drug target discovery

(2011) Nadia M. Penrod et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Mode of action of agomelatine: Synergy between melatonergic and 5-HT2Creceptors

(2011) Giorgio Racagni et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus

(2011) Yosuke Yamawaki et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Genes, Environment, and Individual Differences in Responding to Treatment for Depression

(2011) Rudolf Uher   HARVARD REVIEW OF PSYCHIATRY

The Impact of Psychotherapy, Pharmacotherapy, and Their Combination on Quality of Life in Depression

(2011) Waguih William IsHak et al.   HARVARD REVIEW OF PSYCHIATRY

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

(2010) Christian A. Heidbreder et al.   Annals of the New York Academy of Sciences

National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry

(2010) Ramin Mojtabai et al.   ARCHIVES OF GENERAL PSYCHIATRY

Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial

(2010) Wayne C. Drevets et al.   BIOLOGICAL PSYCHIATRY

Therapeutic Options for Treatment-Resistant Depression

(2010) Richard C. Shelton et al.   CNS DRUGS

Polypharmacy in schizophrenia

(2010) Mathias Zink et al.   CURRENT OPINION IN PSYCHIATRY

Exploration of Structure-Activity Relationships for Dual Serotonin Transporter Reuptake Inhibitors-Histamine H3 Receptor Antagonists

(2010) Emily M. Stocking et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

If at First You Donʼt Succeed

(2010) K. Ryan Connolly et al.   DRUGS

S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: A comparison to aprepitant (MK869) and paroxetine

(2010) Mark J. Millan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Sleep deprivation in depression

(2010) Ulrich-Michael Hemmeter et al.   Expert Review of Neurotherapeutics

Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm

(2010) Severine Farley et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder

(2010) Siegfried Kasper et al.   JOURNAL OF CLINICAL PSYCHIATRY

The Central and Basolateral Amygdala Are Critical Sites of Neuropeptide Y/Y2 Receptor-Mediated Regulation of Anxiety and Depression

(2010) R. O. Tasan et al.   JOURNAL OF NEUROSCIENCE

Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test

(2010) Jesper T Andreasen et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Metabotropic glutamate receptors: From the workbench to the bedside

(2010) F. Nicoletti et al.   NEUROPHARMACOLOGY

Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models

(2010) John H. Kehne et al.   PHARMACOLOGY & THERAPEUTICS

The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

(2010) Erik H.F. Wong et al.   PHARMACOLOGY & THERAPEUTICS

Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis

(2010) J. Guidi et al.   PSYCHOLOGICAL MEDICINE

Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

(2010) Norbert Müller et al.   SCHIZOPHRENIA RESEARCH

Is Pharma Running Out of Brainy Ideas?

(2010) G. Miller   SCIENCE

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Overview of the Genetics of Major Depressive Disorder

(2010) Falk W. Lohoff   Current Psychiatry Reports

Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study

(2009) Pierre Blier et al.   AMERICAN JOURNAL OF PSYCHIATRY

Trace amine-associated receptor 1 as a monoaminergic modulator in brain

(2009) Zhihua Xie et al.   BIOCHEMICAL PHARMACOLOGY

Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT1A receptor antagonist and potential novel antidepressant

(2009) CE Beyer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Serotonin Receptors, Type 4: A New Hope?

(2009) Guillaume Lucas   CURRENT DRUG TARGETS

Epigenetic dysregulation in cognitive disorders

(2009) Johannes Gräff et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain

(2009) Jian-You Guo et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Advantages and disadvantages of combination treatment with antipsychotics

(2009) Guy Goodwin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Tachykinin receptor antagonists in clinical trials

(2009) Laura Quartara et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mecamylamine – a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders

(2009) Ingrid Bacher et al.   EXPERT OPINION ON PHARMACOTHERAPY

Polypharmacy in Children and Adolescents Treated for Major Depressive Disorder

(2009) Roger S. McIntyre et al.   JOURNAL OF CLINICAL PSYCHIATRY

Depressive Illness Burden Associated With Complex Polypharmacy in Patients With Bipolar Disorder

(2009) Joseph F. Goldberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

Antidepressant Actions of Histone Deacetylase Inhibitors

(2009) H. E. Covington et al.   JOURNAL OF NEUROSCIENCE

WS-50030 [7- -1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

(2009) J. A. Brennan et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Trace Amine-Associated Receptors as Emerging Therapeutic Targets

(2009) T. D. Sotnikova et al.   MOLECULAR PHARMACOLOGY

Finding the missing heritability of complex diseases

(2009) Teri A. Manolio et al.   NATURE

From synapse to nucleus: Novel targets for treating depression

(2009) Herbert E. Covington et al.   NEUROPHARMACOLOGY

Cognitive enhancing effects of ghrelin receptor agonists

(2009) Zeenat Atcha et al.   PSYCHOPHARMACOLOGY

Circadian abnormalities, molecular clock genes and chronobiological treatments in depression

(2008) J. N. Bunney et al.   BRITISH MEDICAL BULLETIN

Antidepressant-like effect of 17β-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems

(2008) Ashish Dhir et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Recent Developments in the Design of Anti-Depressive Therapies: Targeting the Serotonin Transporter

(2008) S. Butler et al.   CURRENT MEDICINAL CHEMISTRY

From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage

(2008) S. Giordano et al.   CURRENT MEDICINAL CHEMISTRY

5-HT1 Receptor Augmentation Strategies as Enhanced Efficacy Therapeutics for Psychiatric Disorders

(2008) Lee Dawson et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Potentially Inappropriate Use of Psychotropic Medications in Hospitalized Elderly Patients in France

(2008) Max Prudent et al.   DRUGS & AGING

Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression

(2008) Anton Y. Bespalov et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Glucocorticoid antagonists in neuropsychotic disorders

(2008) Alan F. Schatzberg et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor

(2008) Leah Aluisio et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A regulatory Apologia — A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

(2008) Hans Melander et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonists

(2008) Florence Loiseau et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Genetic and epigenetic defects in mental retardation

(2008) Jamie M. Kramer et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic

(2008) Anna Glezer et al.   JOURNAL OF AFFECTIVE DISORDERS

Nicotinic Antagonist Augmentation of Selective Serotonin Reuptake Inhibitor-Refractory Major Depressive Disorder

(2008) Tony P. George et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress

(2008) Michael Lutter et al.   NATURE NEUROSCIENCE

Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms

(2008) Robert J. DeRubeis et al.   NATURE REVIEWS NEUROSCIENCE

WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent

(2008) Zoë A. Hughes et al.   NEUROPHARMACOLOGY

5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor

(2008) Jonathan Shelton et al.   NEUROPHARMACOLOGY

Neurokinin1 Antagonists Potentiate Antidepressant Properties of Serotonin Reuptake Inhibitors, Yet Blunt Their Anxiogenic Actions: A Neurochemical, Electrophysiological and Behavioral Characterization

(2008) Alain Gobert et al.   NEUROPSYCHOPHARMACOLOGY

NIMH Initiatives to Facilitate Collaborations Among Industry, Academia and Government for the Discovery and Clinical Testing of Novel Models and Drugs for Psychiatric Disorders

(2008) Linda S Brady et al.   NEUROPSYCHOPHARMACOLOGY

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

(2008) Mark J. Millan   Neurotherapeutics

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

(2008) Anne Dekeyne et al.   PSYCHOPHARMACOLOGY

Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138

(2008) Mark J. Millan et al.   THERAPIE

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

(2007) Sungho Maeng et al.   BIOLOGICAL PSYCHIATRY

Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

(2007) Lorna Piazzi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis

(2007) F. Matrisciano et al.   NEUROPHARMACOLOGY